Johanna Myllyharju – CV

Education and positions

1989	Master of Science, University of Turku
1998	Ph.D., University of Turku
1994-1998	Research Scientist, Department of Medical Biochemistry and Molecular Biology, University of Oulu
1999-2002	Academy of Finland Postdoctoral Researcher, University of Oulu
2000	Docent in Molecular Biology, University of Oulu
2002-2007	Academy of Finland Research Fellow, University of Oulu
2004-	Project Leader, Biocenter Oulu
2007-	Professor of Molecular Biology, University of Oulu
2008-	Vice Chair of the Oulu Center for Cell-Matrix Research
2008-2009	1st Vice Director (Research), Institute of Biomedicine, University of Oulu
2010-2012	Chair, Department of Medical Biochemistry and Molecular Biology, University of Oulu
2010-	Scientific Director, Biocenter Oulu, University of Oulu
2012-2017	Deputy Director, Academy of Finland Center of Excellence in Cell-Extracellular Matrix Research

Selected scientific advisory functions

2000-	Collaborating scientist, FibroGen Inc., San Francisco, CA, USA
2004-	Evaluator of grant applications for e.g. Finnish Cultural Foundation, Swedish Research Council, Wellcome Trust (UK), Medical Research Council (UK), Biotechnology and Biological Sciences Research Council (UK), German Research Foundation, Technology Foundation STW (The Netherlands), National Research Agency of France
2008-2013	Member of the Editorial Board, Journal of Biological Chemistry
2009-2013	Member of the Management Committee and Working Group Leader, COST Action TD0901: Hypoxia sensing, signalling and adaptation
2010-2013	Member of the Research Council, University of Oulu
2010-2013	Member of the Faculty Council, Medical Faculty, University of Oulu
2010-	Member of the Board, Biocenter Finland
2010-2015	Member of the Research Council for Health, Academy of Finland, 2nd Vice Chair 2010-2012, 1st Vice Chair 2013-2015
2010-2015	Vice Chair of the Subcommittee for International Joint Projects, Academy of Finland

Selected publications

Myllyharju J, and Kivirikko KI. Characterization of the iron- and 2-oxoglutarate-binding sites of human prolyl 4-hydroxylase. *EMBO J* 16: 1173-1180, 1997.

Hirsilä M, Koivunen P, Günzler V, Kivirikko KI, and Myllyharju J. Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. *J Biol Chem* 278: 30772-30780, 2003.

Qi HH, Ongusaha PP, Myllyharju J, Chen D, Pakkanen O, Shi Y, Lee SW, Peng J, and Shi Y. Prolyl 4-hydroxylation regulates Argonaute 2 stability. *Nature* 455: 421-5, 2008.

Mordechai S*, Gradstein L*, Pasanen A, Ofir R, El Amour K, Levy J, Belfair N, Lifshitz T, Joshua S, Narkis G, Elbedour K, Myllyharju J, and Birk OS. High myopia caused by a mutation in *LEPREL1*, encoding prolyl 3-hydroxylase 2. *Am J Hum Genet* 89: 438-445, 2011. *Equal contribution.

Laitala A, Aro E, Walkinshaw G, Mäki JM, Rossi M, Heikkilä M, Savolainen E-R, Arend M, Kivirikko KI, Koivunen P*, and Myllyharju J*. A transmembrane prolyl 4-hydroxylase is a fourth prolyl 4-hydroxylase regulating erythropoietin production and erythropoiesis. *Blood* 120: 3336-3344, 2012. *Equal contribution.